Published in Lipids on February 06, 2007
Optimal dosing of miltefosine in children and adults with visceral leishmaniasis. Antimicrob Agents Chemother (2012) 0.93
Quantification of miltefosine in peripheral blood mononuclear cells by high-performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2015) 0.79
Functional Validation of ABCA3 as a Miltefosine Transporter in Human Macrophages: IMPACT ON INTRACELLULAR SURVIVAL OF LEISHMANIA (VIANNIA) PANAMENSIS. J Biol Chem (2016) 0.78
Naegleria fowleri: Pathogenesis, Diagnosis, and Treatment Options. Antimicrob Agents Chemother (2015) 0.75
Vagal stimulation rapidly increases leptin secretion in human stomach. Gastroenterology (2002) 1.50
Nanocapsule technology: a review. Crit Rev Ther Drug Carrier Syst (2002) 1.46
Oseltamivir carboxylate accumulation in a patient treated by haemodiafiltration and extracorporeal membrane oxygenation. Intensive Care Med (2010) 1.44
Should moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine model. Antimicrob Agents Chemother (2010) 1.36
Generation of superparamagnetic liposomes revealed as highly efficient MRI contrast agents for in vivo imaging. J Am Chem Soc (2005) 1.29
Leptin counteracts sodium butyrate-induced apoptosis in human colon cancer HT-29 cells via NF-kappaB signaling. J Biol Chem (2004) 1.28
Surface-engineered nanoparticles for multiple ligand coupling. Biomaterials (2003) 1.15
In vitro metabolism of chloroquine: identification of CYP2C8, CYP3A4, and CYP2D6 as the main isoforms catalyzing N-desethylchloroquine formation. Drug Metab Dispos (2003) 1.12
Luminal leptin induces rapid inhibition of active intestinal absorption of glucose mediated by sodium-glucose cotransporter 1. Diabetes (2005) 1.08
Population pharmacokinetics and bioavailability of tacrolimus in kidney transplant patients. Br J Clin Pharmacol (2007) 1.08
Effect of efavirenz on intestinal p-glycoprotein and hepatic p450 function in rats. J Pharm Pharm Sci (2005) 1.04
Nanotechnologies and controlled release systems for the delivery of antisense oligonucleotides and small interfering RNA. Br J Pharmacol (2009) 1.01
Cyclooxygenase-2 inhibitors prevent trinitrobenzene sulfonic acid-induced P-glycoprotein up-regulation in vitro and in vivo. Eur J Pharmacol (2010) 0.99
Placental transfer of lopinavir/ritonavir in the ex vivo human cotyledon perfusion model. Am J Obstet Gynecol (2006) 0.98
Toxicity and antileishmanial activity of a new stable lipid suspension of amphotericin B. Antimicrob Agents Chemother (2003) 0.97
E-selectin as a target for drug delivery and molecular imaging. J Control Release (2011) 0.96
Population pharmacokinetics of tacrolimus in full liver transplant patients: modelling of the post-operative clearance. Eur J Clin Pharmacol (2005) 0.96
Influence of the pro-inflammatory cytokines on P-glycoprotein expression and functionality. J Pharm Pharm Sci (2004) 0.95
Duodenal leptin stimulates cholecystokinin secretion: evidence of a positive leptin-cholecystokinin feedback loop. Diabetes (2003) 0.95
Anti-inflammatory effect of palmitoylethanolamide on human adipocytes. Obesity (Silver Spring) (2009) 0.94
Combination of tenofovir and emtricitabine plus efavirenz: in vitro modulation of ABC transporter and intracellular drug accumulation. Antimicrob Agents Chemother (2008) 0.92
Gastric leptin: a new manager of gastrointestinal function. Curr Opin Pharmacol (2004) 0.92
Influence of polymer behaviour in organic solution on the production of polylactide nanoparticles by nanoprecipitation. Int J Pharm (2007) 0.91
Minocycline and riluzole brain disposition: interactions with p-glycoprotein at the blood-brain barrier. J Neurochem (2007) 0.91
Brain and plasma riluzole pharmacokinetics: effect of minocycline combination. J Pharm Pharm Sci (2009) 0.91
Effect of tumor necrosis factor-alpha and interferon-gamma on intestinal P-glycoprotein expression, activity, and localization in Caco-2 cells. J Pharm Sci (2004) 0.91
Comparison of ABC transporter modulation by atazanavir in lymphocytes and human brain endothelial cells: ABC transporters are involved in the atazanavir-limited passage across an in vitro human model of the blood-brain barrier. AIDS Res Hum Retroviruses (2008) 0.91
Surface-modified and conventional nanocapsules as novel formulations for parenteral delivery of halofantrine. J Nanosci Nanotechnol (2006) 0.90
Functional role of p-glycoprotein and binding protein effect on the placental transfer of lopinavir/ritonavir in the ex vivo human perfusion model. Obstet Gynecol Int (2009) 0.90
Intestinal absorption of miltefosine: contribution of passive paracellular transport. Pharm Res (2007) 0.90
Influence of tumor necrosis factor-alpha on the expression and function of P-glycoprotein in an immortalised rat brain capillary endothelial cell line, GPNT. Biochem Pharmacol (2003) 0.90
ABCG2- and ABCG4-mediated efflux of amyloid-β peptide 1-40 at the mouse blood-brain barrier. J Alzheimers Dis (2012) 0.89
Efficacy and pharmacokinetics of intravenous nanocapsule formulations of halofantrine in Plasmodium berghei-infected mice. Antimicrob Agents Chemother (2004) 0.88
Reduced intestinal absorption of dipeptides via PepT1 in mice with diet-induced obesity is associated with leptin receptor down-regulation. J Biol Chem (2009) 0.88
Improvement of cefpodoxime proxetil oral absorption in rats by an oil-in-water submicron emulsion. Int J Pharm (2003) 0.88
P-glycoprotein expression and function are increased in an animal model of amyotrophic lateral sclerosis. Neurosci Lett (2010) 0.88
Stability of oxaliplatin solution. Ann Pharmacother (2009) 0.86
The in vitro kinetics of the interactions between PEG-ylated magnetic-fluid-loaded liposomes and macrophages. Biomaterials (2007) 0.86
Interactions between riluzole and ABCG2/BCRP transporter. Neurosci Lett (2009) 0.86
Long-term effect of leptin on H+-coupled peptide cotransporter 1 activity and expression in vivo: evidence in leptin-deficient mice. J Pharmacol Exp Ther (2007) 0.86
Impact of extracorporeal membrane oxygenation and continuous venovenous hemodiafiltration on the pharmacokinetics of oseltamivir carboxylate in critically ill patients with pandemic (H1N1) influenza. Ther Drug Monit (2012) 0.85
Polyester-poly(ethylene glycol) nanoparticles loaded with the pure antiestrogen RU 58668: physicochemical and opsonization properties. Pharm Res (2003) 0.85
Once-daily dosing of saquinavir soft-gel capsules and ritonavir combination in HIV-1-infected patients (IMEA015 study). Antivir Ther (2004) 0.84
Efavirenz does not interact with the ABCB1 transporter at the blood-brain barrier. Pharm Res (2006) 0.84
Association between ABCB1 C3435T polymorphism and increased risk of cannabis dependence. Prog Neuropsychopharmacol Biol Psychiatry (2009) 0.84
Therapeutic efficiency of everolimus and lapatinib in xenograft model of human colorectal carcinoma with KRAS mutation. Fundam Clin Pharmacol (2012) 0.83
Population pharmacokinetics of everolimus in cardiac recipients: comedications, ABCB1, and CYP3A5 polymorphisms. Ther Drug Monit (2012) 0.83
Multidrug resistance proteins in gastrointestinal stromal tumors: site-dependent expression and initial response to imatinib. Clin Cancer Res (2005) 0.83
Bioavailability and tissular distribution of docetaxel, a P-glycoprotein substrate, are modified by interferon-alpha in rats. J Pharm Pharmacol (2007) 0.83
Cardiotoxicity reduction induced by halofantrine entrapped in nanocapsule devices. Life Sci (2007) 0.83
MDR-1 C3435T polymorphism influences cyclosporine a dose requirement in liver-transplant recipients. Transplantation (2004) 0.83
Cyclooxygenase inhibitors down regulate P-glycoprotein in human colorectal Caco-2 cell line. Pharm Res (2008) 0.83
Emtricitabine: Inhibitor and substrate of multidrug resistance associated protein. Eur J Pharm Sci (2008) 0.82
Contribution and limit of the model of perfused cotyledon to the study of placental transfer of drugs. Example of a protease inhibitor of HIV: nelfinavir. Eur J Obstet Gynecol Reprod Biol (2009) 0.82
Interaction between miltefosine and amphotericin B: consequences for their activities towards intestinal epithelial cells and Leishmania donovani promastigotes in vitro. Antimicrob Agents Chemother (2006) 0.82
Synthesis and in vitro studies of gold nanoparticles loaded with docetaxel. Int J Pharm (2013) 0.81
Role of two efflux proteins, ABCB1 and ABCG2 in blood-brain barrier transport of bromocriptine in a murine model of MPTP-induced dopaminergic degeneration. J Pharm Pharm Sci (2009) 0.81
Modulation of intestinal barrier properties by miltefosine. Biochem Pharmacol (2005) 0.81
Intestinal inflammation induces adaptation of P-glycoprotein expression and activity. Biochem Pharmacol (2005) 0.81
Development of oil-in-water microemulsions for the oral delivery of amphotericin B. Int J Pharm (2013) 0.80
Interleukin-2 treatment effect on imatinib pharmacokinetic, P-gp and BCRP expression in mice. Anticancer Drugs (2010) 0.80
Cetuximab increases concentrations of irinotecan and of its active metabolite SN-38 in plasma and tumour of human colorectal carcinoma-bearing mice. Fundam Clin Pharmacol (2014) 0.79
Prediction tacrolimus blood levels based on the Bayesian method in adult kidney transplant patients. Eur J Drug Metab Pharmacokinet (2011) 0.79
Effect of interleukin-2 on intestinal P-glycoprotein expression and functionality in mice. J Pharmacol Exp Ther (2002) 0.79
Rosiglitazone and metformin have opposite effects on intestinal absorption of oligopeptides via the proton-dependent PepT1 transporter. Mol Pharmacol (2011) 0.78
Pharmacokinetics of a tri-glucoconjugated 5,10,15-(meta)-trihydroxyphenyl-20-phenyl porphyrin photosensitizer for PDT. A single dose study in the rat. J Photochem Photobiol B (2006) 0.78
Effect of hr-IL2 treatment on intestinal P-glycoprotein expression and activity in Caco-2 cells. J Pharm Pharmacol (2002) 0.78
New lipid formulation of amphotericin B: spectral and microscopic analysis. Biochim Biophys Acta (2004) 0.78
Pharmacokinetics of propofol administered by target-controlled infusion to alcoholic patients. Anesthesiology (2003) 0.78
Potentiation of mivacurium blockade by low dose of pancuronium: a pharmacokinetic study. Anesthesiology (2003) 0.78
Aerosolized liposomal amphotericin B: prediction of lung deposition, in vitro uptake and cytotoxicity. Int J Pharm (2012) 0.78
A new UPLC-MS/MS method for the determination of irinotecan and 7-ethyl-10-hydroxycamptothecin (SN-38) in mice: application to plasma and brain pharmacokinetics. J Pharm Biomed Anal (2012) 0.78
Irinotecan and temozolomide brain distribution: a focus on ABCB1. Cancer Chemother Pharmacol (2014) 0.78
Effect of oil-in-water submicron emulsion surface charge on oral absorption of a poorly water-soluble drug in rats. Drug Deliv (2008) 0.78
Putative effect of Helicobacter pylori and gastritis on gastric acid secretion in cat. Am J Physiol Gastrointest Liver Physiol (2002) 0.78
The tripeptide KdPT protects from intestinal inflammation and maintains intestinal barrier function. Am J Pathol (2011) 0.78
Modification of the P-glycoprotein dependent pharmacokinetics of digoxin in rats by human recombinant interferon-alpha. Pharm Res (2005) 0.78
MDR1A (ABCB1)-deficient CF-1 mutant mice are susceptible to cerebral malaria induced by Plasmodium berghei ANKA. J Parasitol (2008) 0.77
Interactions between the dopamine agonist, bromocriptine and the efflux protein, P-glycoprotein at the blood-brain barrier in the mouse. Eur J Pharm Sci (2005) 0.77
Trends in rheumatic fever: clinical aspects and perspectives in prophylactic treatments. Expert Opin Drug Deliv (2012) 0.77
Regulation of the oligopeptide transporter, PEPT-1, in DSS-induced rat colitis. Dig Dis Sci (2007) 0.77
Disposition of Delta tetrahydrocannabinol in CF1 mice deficient in mdr1a P-glycoprotein. Addict Biol (2008) 0.77
Physicochemical characterization of molecular assemblies of miltefosine and amphotericin B. Mol Pharm (2007) 0.77
MDR1 polymorphism role in patients treated with cetuximab and irinotecan in irinotecan refractory colorectal cancer. Med Oncol (2009) 0.77
Disturbed intestinal nitrogen homeostasis in a mouse model of high-fat diet-induced obesity and glucose intolerance. Am J Physiol Endocrinol Metab (2014) 0.77